









Markets
/
Stocks
/
nasdaq-onc
/

Beigene Ltd

ONC

View Detailed Chart

269.630USD

-6.899-2.50%

Close 06/13, 16:00（ET）Quotes delayed by 15 min

26.72BMarket Cap

LossP/E TTM



Beigene Ltd

269.630

-6.899-2.50%

Company

Intraday

30m

Today

-2.50%

5 Days

+5.38%

1 Month

+22.59%

6 Months

+50.34%

Year to Date

+45.97%

1 Year

+65.84%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 23 analysts

BUY

Current Rating

323.099

Target Price

31.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

557

Total

Median

Average

Company name

Ratings

Analysts

Beigene Ltd

ONC

Exact Sciences Corp

EXAS

CRISPR Therapeutics AG

CRSP

Regeneron Pharmaceuticals Inc

REGN

Intellia Therapeutics Inc

NTLA

Moderna Inc

MRNA

...

112

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(2)

Neutral(2)

Buy(9)

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

5.689

Buy

RSI(14)

64.931

Neutral

STOCH(KDJ)(9,3,3)

70.311

Neutral

ATR(14)

8.862

Low Volatility

CCI(14)

104.803

Buy

Williams %R

30.270

Buy

TRIX(12,20)

0.450

Sell

StochRSI(14)

3.263

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

267.154

Buy

MA10

260.455

Buy

MA20

249.541

Buy

MA50

242.234

Buy

MA100

243.883

Buy

MA200

222.866

Buy

News

More news coming soon, stay tuned...

Company

BeiGene, Ltd. is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. The Company has an oncology pipeline of more than 50 investigational assets. Its products include BRUKINSA, TEVIMBRA, XGEVA, BLINCYTO, KYPROLIS, POBEVCY, and others. BRUKINSA is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). TEVIMBRA is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is engaged in the sale of XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen and POBEVCY in China under a license from Bio-Thera. The Company’s pipeline products include Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, Xaluritamig, and others.

Ticker SymbolONC

CompanyBeigene Ltd

CEOMr. John Victor Oyler

Websitehttps://www.beigene.com/